Kimberly-Clark stock heads into the open after a 0.3% slip

At the close on September 11, 2026, Kimberly-Clark stock ended at USD 98.19 on its primary Cboe listing, down 0.3% for the day, while the S&P 500 edged higher. The shares remain about 6.5% below their level at the start of 2026 as investors track the Kenvue deal and EU review.

Kimberly-Clark stock closed at USD 98.19 on the Cboe on September 11, 2026, marking a 0.3% decline for that session compared with the prior close in the same venue. Per Cboe data cited in recent market coverage, this level leaves the shares roughly 6.5% below their starting point for 2026, underscoring a year-to-date lag versus the broader market. In the same September 11, 2026 session, the S&P 500 index finished slightly higher, so Kimberly-Clark stock underperformed the reference benchmark on that day.

September 11, 2026 in numbers

Kimberly-Clark Corp. (ISIN US4943681035, Cboe: KMB) closed the September 11, 2026 session at USD 98.19 on its primary Cboe listing in USD, reflecting a 0.3% daily loss that aligned with commentary in a market wrap carried by Ad-hoc-news based on Cboe data. As Ad-hoc-news reported on September 14, 2026, this close left the stock about 6.46% below its level at the start of 2026, highlighting a moderate year-to-date decline even as the company pursues a large strategic transaction.

The same overview noted that the USD 98.19 closing price on September 11, 2026 sat within Kimberly-Clark stock's recent trading band and captured the last completed Cboe session before the start of the new week, with the S&P 500 index edging up for that day, indicating relative underperformance by Kimberly-Clark shares. Per Cboe data referenced in that recap, the stock's move on September 11, 2026 was modest in absolute terms but formed part of a broader pattern of mid-single-digit percentage underperformance since the turn of the year.

Regulatory scrutiny over the Kenvue deal today

Today, investor attention around Kimberly-Clark stock is shaped by continuing regulatory scrutiny of the company's proposed acquisition of Kenvue and the potential asset sales being prepared to secure approval. As Reuters reported on September 14, 2026, Kimberly-Clark is readying concessions, including potential asset sales, to address European Commission antitrust concerns over its roughly USD 40 billion bid for Tylenol maker Kenvue, with the regulator expected to outline its objections this week and a preliminary review running until September 29, 2026. A summary by Finimize emphasized that these remedies could determine whether the transaction clears during the initial phase or proceeds to an extended investigation, making the EU competition review a key backdrop for Kimberly-Clark stock into today's US session.